Senzo, Inc.

Senzo, Inc. develops innovative diagnostic technologies aimed at improving healthcare accessibility through rapid testing solutions. Their flagship product, the Amplified Lateral Flow test, provides high-accuracy diagnostics for various infectious diseases. Senzo, Inc.

was founded in 2014 in Newtown Square, US, focusing on advanced diagnostic solutions. The company has raised a total of USD 1. 80 mn through a Seed round in October 2023, valuing it at USD 24. 70 mn post-money.

Senzo has completed 6 deals to date and has not reported any significant pivots or changes in business operations. Senzo Health specializes in high-accuracy, low-cost point-of-care diagnostic technologies, primarily focusing on its flagship Amplified Lateral Flow (ALF) test. This innovative test offers PCR-accurate diagnostics for infectious diseases such as COVID-19, HIV, and Tuberculosis, providing rapid results within minutes. Targeted at healthcare providers, laboratories, and institutions, Senzo's ALF technology enhances accessibility, especially in low-income areas, addressing public health needs for timely diagnostics.

Senzo Health's revenue model is driven by the sales of its diagnostic products, particularly the ALF tests, which are sold through a B2B model to healthcare facilities and laboratories. Bulk purchases are common, with contractual agreements in place to ensure supply amidst high demand. Their pricing structure reflects the advanced accuracy of their technology, positioning Senzo competitively against traditional laboratory tests and bolstered by partnerships with organizations like the Biomedical Advanced Research and Development Authority (BARDA). In October 2023, Senzo, Inc.

secured USD 1. 8 mn in Seed funding, which will be directed towards continued operations and development initiatives. The company plans to enhance its product line and expand into new markets, including regions in Europe and Asia, aiming for strategic launches in the coming year. This funding will support these expansion efforts as Senzo continues to address the healthcare sector's demand for reliable diagnostic solutions.